CAPTRUST Financial Advisors’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
Other funds holding MYGN
CAPTRUST Financial Advisors's MYGN Position: Q3 2026 in Review
CAPTRUST Financial Advisors sold out of Myriad Genetics (MYGN) in Q3 2026, closing a stake of 25,261 shares — an estimated $144K sold.
CAPTRUST Financial Advisors first reported a position in MYGN in Q3 2019 and held it in 21 quarters. The position peaked at $509K in Q4 2023. 126 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.
- CAPTRUST Financial Advisors reported no remaining Myriad Genetics position as of Q3 2026 after selling out during the quarter.
- CAPTRUST Financial Advisors sold 25,261 Myriad Genetics shares in Q3 2026, an estimated $144K.
- CAPTRUST Financial Advisors first reported a position in Myriad Genetics in Q3 2019 and held it in 21 quarters.
- CAPTRUST Financial Advisors's Myriad Genetics position peaked at $509K in Q4 2023.
- 126 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.